Ramon Leon, MD
Family Medicine · Miami, FLNPI 1073694337
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$521
- Pfizer$434
- Novo Nordisk$433
- Lilly USA, LLC$342
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$219
- Astellas Pharma US Inc$173
- plus $962 from 17 others
Across 402 payments — averaging $16,101 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.6M
- AbbVie$1.3M
- Eli Lilly$1.1M
- E.r. Squibb & Sons, L.L.C.$945K
- Gilead$311K
- Novo Nordisk AS$222K
- plus $1.1M from 14 others
What the payments were for
- Food & beverage$2,98397%
- Education$1013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $521 |
| Pfizer | 22 | $434 |
| Novo Nordisk | 21 | $433 |
| Lilly USA, LLC | 20 | $342 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $219 |
| Astellas Pharma US Inc | 5 | $173 |
| GSK | 6 | $145 |
| Abbott | 6 | $109 |
| Bayer | 5 | $107 |
| AbbVie(2 entities) | 4 | $88 |
| Amarin Pharma, Inc. | 5 | $79 |
| Idorsia Pharmaceuticals US Inc | 3 | $67 |
| Johnson & Johnson | 3 | $64 |
| Boehringer Ingelheim | 3 | $59 |
| Dexcom, Inc. | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Amgen | 2 | $40 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Corium, LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$3,085 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 221 | $260,513 |
| OzempicSemaglutide | 124 | $140,688 |
| EliquisApixaban | 114 | $119,115 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $84,088 |
| JardianceEmpagliflozin | 52 | $80,275 |
| FarxigaDapagliflozin Propanediol | 76 | $68,686 |
| JanuviaSitagliptin Phosphate | 45 | $54,591 |
| XareltoRivaroxaban | 31 | $39,216 |
| TrulicityDulaglutide | 20 | $32,551 |
| VascepaIcosapent Ethyl | 44 | $24,585 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 23 | $22,902 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $22,262 |
| RybelsusSemaglutide | 12 | $22,147 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $13,742 |
| LinzessLinaclotide | 11 | $13,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $342 | $293,064241 claims |
| Novo NordiskOzempic, Rybelsus | $433 | $162,835136 claims |
| MerckJanumet, Januvia, Janumet Xr | $17 | $161,582137 claims |
| PfizerEliquis | $434 | $119,115114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $521 | $87,356101 claims |
| Boehringer IngelheimJardiance | $59 | $80,27552 claims |
| Johnson & JohnsonXarelto | $64 | $39,21631 claims |
| AbbVieLinzess, Synthroid | $88 | $19,68466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.